Inhibition of Aquaporin 4 Decreases Amyloid Aβ40 Drainage Around Cerebral Vessels.
Amyloid
/ metabolism
Amyloid beta-Peptides
/ metabolism
Animals
Aquaporin 4
/ antagonists & inhibitors
Basement Membrane
/ drug effects
Blood-Brain Barrier
/ drug effects
Brain
/ blood supply
Capillary Permeability
/ drug effects
Fluorescence
Immunoglobulins
/ metabolism
Male
Mice, Inbred C57BL
Niacinamide
/ analogs & derivatives
Thiadiazoles
/ pharmacology
Alzheimer’s disease
Amyloid
Aquaporin 4
Aβ40
Perivascular drainage
TGN-020
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
18
02
2020
accepted:
24
07
2020
pubmed:
13
8
2020
medline:
30
6
2021
entrez:
13
8
2020
Statut:
ppublish
Résumé
Aquaporin-4 (AQP4) is located mainly in the astrocytic end-feet around cerebral blood vessels and regulates ion and water homeostasis in the brain. While deletion of AQP4 is shown to reduce amyloid-β (Aβ) clearance and exacerbate Aβ peptide accumulation in plaques and vessels of Alzheimer's disease mouse models, the mechanism and clearing pathways involved are debated. Here, we investigated how inhibiting the function of AQP4 in healthy male C57BL/6 J mice impacts clearance of Aβ40, the more soluble Aβ isoform. Using two-photon in vivo imaging and visualizing vessels with Sulfurodamine 101 (SR101), we first showed that Aβ40 injected as a ≤ 0.5-μl volume in the cerebral cortex diffused rapidly in parenchyma and accumulated around blood vessels. In animals treated with the AQP4 inhibitor TGN-020, the perivascular Aβ40 accumulation was significantly (P < 0.001) intensified by involving four times more vessels, thus suggesting a generalized clearance defect associated with vessels. Increasing the injecting volume to ≥ 0.5 ≤ 1 μl decreased the difference of Aβ40-positive vessels observed in non-treated and AQP4 inhibitor-treated animals, although the difference was still significant (P = 0.001), suggesting that larger injection volumes could overwhelm intramural vascular clearance mechanisms. While both small and large vessels accumulated Aβ40, for the ≤ 0.5-μl volume group, the average diameter of the Aβ40-positive vessels tended to be larger in control animals compared with TGN-020-treated animals, although the difference was non-significant (P = 0.066). Using histopathology and ultrastructural microscopy, no vascular structural change was observed after a single massive dose of TGN-020. These data suggest that AQP4 deficiency is directly involved in impaired Aβ brain clearance via the peri-/para-vascular routes, and AQP4-mediated vascular clearance might counteract blood-brain barrier abnormalities and age-related vascular amyloidopathy.
Identifiants
pubmed: 32783141
doi: 10.1007/s12035-020-02044-8
pii: 10.1007/s12035-020-02044-8
pmc: PMC7515968
doi:
Substances chimiques
2-(nicotinamide)-1,3,4-thiadiazole
0
Amyloid
0
Amyloid beta-Peptides
0
Aquaporin 4
0
Immunoglobulins
0
Thiadiazoles
0
Niacinamide
25X51I8RD4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4720-4734Références
Brain Struct Funct. 2013 Jan;218(1):39-50
pubmed: 22193336
Acta Neuropathol Commun. 2019 May 8;7(1):74
pubmed: 31068220
J Neurosurg. 2019 May 17;:1-14
pubmed: 31100725
BMJ. 2010 Aug 05;341:c3885
pubmed: 20688841
Neuroscience. 2010 Apr 28;167(1):60-7
pubmed: 20132873
Crit Rev Neurobiol. 1991;6(3):149-82
pubmed: 1773451
J Physiol. 2012 Aug 15;590(16):3665-75
pubmed: 22641787
Brain Pathol. 2014 Sep;24(5):475-93
pubmed: 24571080
Acta Neuropathol. 2018 Jul;136(1):139-152
pubmed: 29754206
Acta Neuropathol. 2011 Apr;121(4):431-43
pubmed: 21259015
Ann Neurol. 2014 Dec;76(6):837-44
pubmed: 25205593
Mol Pharmacol. 2011 Jul;80(1):32-9
pubmed: 21454448
Int J Mol Sci. 2017 Dec 23;19(1):
pubmed: 29295526
Sci Rep. 2016 May 06;6:25658
pubmed: 27149947
Free Radic Biol Med. 2001 Jan 1;30(1):119-28
pubmed: 11134902
Acta Neuropathol. 1989;78(6):572-84
pubmed: 2683563
Genes Brain Behav. 2008 Feb;7 Suppl 1:67-82
pubmed: 18184371
Nat Med. 2000 Jul;6(7):718-9
pubmed: 10888892
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Mol Neurodegener. 2015 Nov 02;10:58
pubmed: 26526066
Mol Neurobiol. 2016 Oct;53(8):5300-9
pubmed: 26433375
Neuroscience. 2004;128(1):27-38
pubmed: 15450351
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6
pubmed: 9751776
Acta Neuropathol. 2016 May;131(5):725-36
pubmed: 26975356
Curr Protein Pept Sci. 2004 Feb;5(1):19-31
pubmed: 14965318
Nat Rev Neurosci. 2013 Apr;14(4):265-77
pubmed: 23481483
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
Alzheimers Dement (N Y). 2015 Jul 26;1(2):122-130
pubmed: 29854932
J Clin Invest. 2000 Dec;106(12):1489-99
pubmed: 11120756
Curr Alzheimer Res. 2016;13(9):952-63
pubmed: 26971934
J Neurochem. 2005 Oct;95(1):254-62
pubmed: 16181429
Exp Neurol. 1999 Aug;158(2):328-37
pubmed: 10415140
J Neuroimmunol. 2012 Oct 15;251(1-2):39-44
pubmed: 22796178
Nat Rev Neurosci. 2011 Nov 03;12(12):723-38
pubmed: 22048062
Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17815-20
pubmed: 21990350
FASEB J. 2001 Nov;15(13):2433-44
pubmed: 11689468
Neurobiol Aging. 2004 May-Jun;25(5):589-97; discussion 603-4
pubmed: 15172734
Nat Rev Drug Discov. 2014 Apr;13(4):259-77
pubmed: 24625825
Neurol Sci. 2011 Feb;32(1):113-6
pubmed: 20924629
Methods Mol Biol. 2017;1559:367-375
pubmed: 28063057
Pediatr Nephrol. 2007 Jun;22(6):778-84
pubmed: 17347837
Nat Med. 2003 Jul;9(7):907-13
pubmed: 12808450
J Cell Mol Med. 2008 Oct;12(5B):1848-62
pubmed: 18624777
FASEB J. 2014 Feb;28(2):705-14
pubmed: 24186965
J Biol Chem. 2001 Aug 17;276(33):31233-7
pubmed: 11406631
J Clin Invest. 2013 Mar;123(3):1299-309
pubmed: 23434588
Neuroreport. 2018 Jun 13;29(9):697-703
pubmed: 29481527
Lancet Neurol. 2014 Aug;13(8):788-94
pubmed: 25030513
J Neuroimmunol. 2004 May;150(1-2):20-8
pubmed: 15081245
J Neuroimaging. 2013 Apr;23(2):219-23
pubmed: 22817997
Nat Med. 2000 Feb;6(2):159-63
pubmed: 10655103
J Cereb Blood Flow Metab. 2013 Dec;33(12):1983-92
pubmed: 24045402
Curr Biol. 2013 Jan 21;23(2):R52-5
pubmed: 23347934
Biochimie. 2009 Oct;91(10):1212-7
pubmed: 19332103
Oxid Med Cell Longev. 2014;2014:795375
pubmed: 24683437
J Neuropathol Exp Neurol. 2003 Dec;62(12):1287-301
pubmed: 14692704
J Anat. 1997 Oct;191 ( Pt 3):337-46
pubmed: 9418990
Br J Cancer. 2002 Sep 9;87(6):621-3
pubmed: 12237771
Neuroscience. 2009 Mar 31;159(3):1055-69
pubmed: 19356689
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):573-9
pubmed: 11818406
Glia. 2017 Jun;65(6):964-973
pubmed: 28317216
Neuropathol Appl Neurobiol. 2008 Apr;34(2):131-44
pubmed: 18208483
Acta Neuropathol. 2011 Sep;122(3):293-311
pubmed: 21688176
Acta Neuropathol. 2018 May;135(5):681-694
pubmed: 29574591
J Neurosci. 2005 Dec 14;25(50):11495-503
pubmed: 16354907
Curr Pharm Des. 2017;23(33):4948-4957
pubmed: 28714415
Br J Pharmacol. 2012 Sep;167(2):324-52
pubmed: 22646481
J Neurosci. 1998 Apr 1;18(7):2506-19
pubmed: 9502811
Curr Health Sci J. 2019 Apr-Jun;45(2):218-226
pubmed: 31624651
Front Biosci (Elite Ed). 2013 Jan 01;5:167-77
pubmed: 23276979
Nat Med. 2000 Feb;6(2):143-50
pubmed: 10655101